Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Hager salah el din
the role of metformin when combined with traditional metastatic breast cancer treatment in non-diabetic patients compared to diabetic patients who are not using metformin. In this randomized control study, there will be a demonstration either it is effective to suppress tumor burden or not through normal screening for tumor.
Age
18–75
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
The non-diabetic patients will be included in the study if they meet the following criteria:
1. Confirmed metastatic breast cancer (IV stage) radiologically or by clinical evaluation receiving chemotherapy
2. Age between 18- 70 years.
3. Life expectancy at least 6 months
You may not be if
The patients will be excluded from the study if they have the following criteria:
1. Bad prognosis disease: Criteria defined as the following
* If patient \>70 years
* If patient has bad site metastasis (brain)
2. Hypersensitivity for metformin: if happened patient will be treated as following
• Pheniramine Maleate 3 times daily for 7 days and Tablet Dexamethasone 1mg daily in 2 divided doses for 5 days \[16\].
3. Any condition associated with increased risk of metformin-associated lactic acidosis (e.g., congestive heart failure defined as New York Heart Association {NYHA} Class III or IV functional status; the history of acidosis of any type, severe infections, kidney or liver disease, respiratory disease, seizures .
4. Diabetic patients.
Clareo Health | Evaluation of the Effect of Metformin on Metastatic Breast Cancer as Adjuvant Treatment
